Related Experiment Video
Updated: Jun 25, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
The future of multiple sclerosis treatment
1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA. cohenj@ccf.org
Journal of the Neurological Sciences
|February 10, 2009
Summary
Recent advances in understanding multiple sclerosis pathophysiology highlight extralesional pathology and immune cell roles. New therapies are emerging, offering potential benefits but also safety considerations for this complex neurological disease.
Area of Science:
- Neurology
- Immunology
- Neuroscience
Background:
- Multiple sclerosis (MS) pathophysiology understanding has evolved significantly.
- New concepts include extralesional pathology, inflammation-neurodegeneration interplay, and disease heterogeneity.
- Additional immune cell populations are recognized as contributors to MS pathology.
Purpose of the Study:
- To review recent advancements in multiple sclerosis pathophysiology.
- To discuss the development of novel therapeutic strategies and outcome measures for MS clinical trials.
- To explore the potential benefits and risks of emerging immunomodulatory, immunosuppressive, neuroprotective, and repair strategies.
Main Methods:
- Literature review of recent scientific publications on multiple sclerosis.
- Analysis of evolving concepts in MS pathophysiology.
- Evaluation of current and developing therapeutic agents for MS.
Main Results:
- Increased recognition of extralesional pathology and its role in MS.
- Understanding of the interplay between inflammatory and neurodegenerative processes in MS.
- Identification of diverse immune cell populations contributing to MS pathogenesis.
- Development of numerous new immunomodulatory and immunosuppressive agents for MS treatment.
- Emergence of neuroprotective and repair strategies for MS.
Conclusions:
- Advances in understanding MS pathophysiology are driving the development of new treatments.
- Emerging therapies offer potential advantages but require careful risk-benefit assessment.
- Further research into MS heterogeneity and underlying mechanisms is crucial.
- The future landscape of MS treatment will be shaped by the efficacy and safety profiles of novel agents.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.